FOLH1 and neoplasm: However, tumor-associated vessels immunolabeled with PSMA in all cases, including four cases (4/7, 66.7%) with moderate (2+) to strong (3+) intensity, and three cases (3/7, 33.3%) with weak (1+) immunostaining.